Can vitamin d and yeast fiber tame diabetes and protect the heart?

NCT ID NCT06861062

Recruiting now Disease control Sponsor: Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether taking vitamin D3 or yeast beta-glucan daily for two years can improve blood sugar control and lower the 10-year risk of heart disease in 2,500 adults aged 40–79 with type 2 diabetes. Participants will be randomly assigned to receive one of the supplements or a placebo, and researchers will track changes in HbA1c and heart risk scores. The goal is to find a simple, low-cost way to help manage diabetes and prevent complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vitamin D3 (cholecalciferol) and yeast beta-glucan
What this could lead to: If it works, this could show that simple daily supplements help manage blood sugar and lower heart disease risk in people with type 2 diabetes.
What could go wrong: This is a large but early-stage trial with no phase designation. Supplements may have only small effects, and results may not apply to everyone with diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Guangxi Medical College
RECRUITING

Nanning, Guangxi, China
Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430000, China
Kailuan General Hospital
RECRUITING

Tangshan, Hebei, China
Sichuan University
RECRUITING

Chengdu, Sichuan, China
Sinopharm Dongfeng General Hospital
RECRUITING

Shiyan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.